Although predictive tools to identify those at risk of disease progression are in their infancy, the development of such tools is crucial for improving patient outcomes.
The GENESIS trial reported substantially better stem cell mobilization when patients with multiple myeloma received motixafortide alongside filgrastim.
Adding quizartinib to standard induction chemotherapy significantly improves overall survival in patients with newly diagnosed acute myeloid leukemia regardless of prior stem cell transplantation.